MetaCap

Vor Biopharma Inc. (VOR)

NASDAQ: VORHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

19.19+0.67 (+3.62%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

VOR stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
$300.56
52-week range
7.21 – 26.00
Day range
17.99 – 19.91
Volume / Avg
1.55M / 945.67K
Beta
—

52-week range

$7.21$26.00

VOR stock today

On Nov 20, VOR ended the session at $19.19, adding $0.67 (3.62%), versus the S&P 500's 3.70% decline. Shares are 26.2% below their 52-week high of $26.00, set on Sep 8, 2026 and 166.2% above the 52-week low of $7.21, in the middle of the past year's range. VOR is up 46.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 157.6%.

Vor Biopharma trades at 0.1x its trailing twelve-month earnings per share of $300.56.

Summary generated from market data by MetaCap's automated system. Methodology

About Vor Biopharma

Company profile

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Jean-Paul Kress M.D.
Headquarters
Boston, MA
Employees
76
IPO year
2021
Website
vorbio.com

Financial highlights

Full financials

Vor Biopharma reported a net loss of $696.0 million, compared with a loss of $116.9 million a year earlier. Diluted earnings per share came in at -$70.50.

Vor Biopharma annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-695.98M$-116.91M$-117.86M$-92.09M$-68.90M
EPS (diluted)$-70.50$-34.03$-1.75$-2.33$-2.10

Analyst forecast

Forecast

Consensus (10 analysts)

strong_buy

Avg. price target

$39.00+103.23%

  • Strong buy 1
  • Buy 8
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $27.00High $50.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-1.45 vs $-0.81
Surprise
-79.01%

VOR news

All VOR news

Vor Biopharma peers

Health Care sector
VOR peer companies
CompanyPrice% ChgMarket capCompare
TSHATaysha Gene Therapies Inc.3.72-1.33%$1.21Bvs VOR
NVAXNovavax Inc.7.47-3.24%$1.23Bvs VOR
INBXInhibrx Biosciences Inc.68.97-7.21%$1.02Bvs VOR
IMCRImmunocore Holdings plc ADR26.41-0.83%$1.36Bvs VOR
MESOMesoblast Limited ADR10.89-2.59%$1.41Bvs VOR
WWBWindward Bio Group AG24.29+1.15%$1.45Bvs VOR
ALVOAlvotech4.12-3.96%$1.47Bvs VOR
IMTXImmatics N.V.5.77-3.03%$878.58Mvs VOR

Indexes, lists and sector

Vor Biopharma stock FAQ

What is Vor Biopharma's stock price today?

VOR last traded at $19.19 as of Nov 20, 4:00 PM EST, up 3.62% on the day. Prices are delayed at least 15 minutes.

Does Vor Biopharma pay a dividend?

No. Vor Biopharma does not currently pay a regular cash dividend.

What is VOR's P/E ratio?

VOR trades at a trailing P/E ratio of 0.06.

Who is Vor Biopharma's CEO?

Dr. Jean-Paul Kress M.D. is the chief executive officer of Vor Biopharma Inc., which has about 76 employees.

Has VOR ever split its stock?

Yes. The most recent VOR stock split was a 1-for-20 split on Sep 19, 2025.

What is the VOR 52-week high?

The 52-week high for VOR is $26.00 and the 52-week low is $7.21. The stock is currently 26.2% below its high.

Compare VOR